Search

Displaying results 4991 - 5000 of 5895 in total
  1. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

  2. Drug

    Lomerizine

    go.drugbank.com/drugs/DB14065
    Experimental

    [A245383] This drug is used to prophylactically treat migraines[A245368, A245373] and is also being investigated against eye-related diseases that are associated with local circulatory disturbances, an

  3. Drug

    Efavaleukin alfa

    go.drugbank.com/drugs/DB16149
    Investigational

    Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker.

  4. Drug

    Reproxalap

    go.drugbank.com/drugs/DB16688
    Investigational

    [L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990]

  5. Drug

    Mepiprazole

    go.drugbank.com/drugs/DB09197
    Experimental

    It acts as a 5-HT2A and α1-adrenergic receptor antagonist, and has also been shown to inhibit the reuptake and induce the release of serotonin, dopamine, and norepinephrine to varying extents.

  6. Drug

    Pefloxacin

    go.drugbank.com/drugs/DB00487
    Approved

    A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.

  7. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy intended to treat Canavan disease. … It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA).

  8. Drug

    Bicifadine

    go.drugbank.com/drugs/DB04889
    Investigational

    Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.

  9. Drug

    BGB-DXP593

    go.drugbank.com/drugs/DB16357
    Investigational

    currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate

  10. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).